× About the Journal Scope of the Journal SPER Publications Editorial Board Abstracting and Indexing Articles in Press Current Issue Archives Submit Article Author Guidelines Advertise Join as Reviewer Contact Editorial Policies and Peer Review Process Journal Policies Publishing Ethics


Review Article
Year : 2019   |  Volume : 11  |  Issue : 2  |  Page : 43-45

Potential non-biological therapeutic options for coronavirus disease-2019: Recent updates

Coronavirus disease-2019 (COVID-19) has been spread across the world and reached to the pandemic level. It has proved as a serious threat to the humanity, therefore, understanding of the ongoing situation and the development of stringent strategies to cure the same is of prime concern. As the potential vaccines development is in continuation, various non-biological therapeutic agents which are being investigated against COVID-19 as a current strategy for symptomatic treatment should be uncovered. To date, various drugs that are approved by the USFDA for their therapeutic effects against rheumatoid arthritis, malaria, influenza A and B and AIDS viruses, pancreatitis, chronic hepatitis C, Middle East respiratory syndrome, inflammation, and immunosuppression are deliberately being used to treat COVID-19 infection. These drugs have shown promising results against this deadly virus. In addition to remdesivir and hydroxychloroquine, oral chlorine dioxide, fluvoxamine, methylprednisolone, losartan, dapagliflozin, and many more have been enrolled for clinical trial and currently recruiting the patients for the studies. This report highlights the potential non-biological therapeutic options used for the treatment of COVID-19, which is expected to help formulation and development scientists to come up with the new technologies of these molecules for better effect against this infectious disease.
Print this article     Email this article